Curated News
By: NewsRamp Editorial Staff
May 28, 2025
Oragenics Announces 1-for-30 Reverse Stock Split to Enhance Market Profile
TLDR
- Oragenics (NYSE American: OGEN) approved a 1-for-30 reverse stock split to boost share price and attract long-term investors.
- The reverse stock split of Oragenics consolidates every 30 shares into one, effective June 3, 2025.
- Oragenics' action to enhance its capital markets profile aims to advance treatments for brain-related health conditions, making tomorrow healthier.
- Oragenics' reverse stock split aims to increase appeal to investors by consolidating shares, an interesting strategy in the stock market.
Impact - Why it Matters
This news matters as the reverse stock split by Oragenics aims to increase the company's share price and attract long-term investors. It reflects the company's commitment to advancing treatments for brain-related health conditions and improving its capital markets profile.
Summary
Oragenics (NYSE American: OGEN) has approved a 1-for-30 reverse stock split of its common shares to boost share price and appeal to investors. CEO Janet Huffman notes the move aligns with the company's strategy to enhance its capital markets profile and advance treatments for brain-related health conditions.
Oragenics is a biotechnology company focusing on nasal delivery of pharmaceutical medications in neurology and infectious diseases, with drug candidates for mTBI and NPC. The split will take effect on June 3, 2025, under the existing symbol 'OGEN' with a new CUSIP number.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Oragenics Announces 1-for-30 Reverse Stock Split to Enhance Market Profile
